Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Yue Wen, Han Wang, Dean Tian, Ge Wang
Inflammatory bowel disease (IBD) is a chronic nonspecific inflammatory disease of the gastrointestinal tract, and its pathogenesis has not been fully understood. Extensive dysregulation of the intestinal mucosal immune system is critical in the development and progression of IBD. T helper (Th) 17 cells have the characteristics of plasticity. They can transdifferentiate into subpopulations with different functions in response to different factors in the surrounding environment, thus taking on different roles in regulating the intestinal immune responses...
2024: Therapeutic Advances in Gastroenterology
#22
JOURNAL ARTICLE
Helena Gensmyr-Singer, Mårten Werner, Pontus Karling
BACKGROUND: Thiopurines are commonly used to treat inflammatory bowel disease but withdrawal due to side effects are common. Thioguanine has been suggested to be better tolerated than conventional thiopurines. OBJECTIVES: We studied drug-survival of low dose of thioguanine in real-life clinical practice in comparison to conventional thiopurines. DESIGN: Retrospective observational study. METHODS: All patients born 1956 and later, and who at least once started thiopurine treatment between 2006 and 2022 were included...
2024: Therapeutic Advances in Gastroenterology
#23
JOURNAL ARTICLE
Eduard Brunet-Mas, Belen Garcia-Sagué, Emli Vela, Luigi Melcarne, Laura Patricia Llovet, Caridad Pontes, Pilar García-Iglesias, Anna Puy, Sergio Lario, Maria Jose Ramirez-Lazaro, Albert Villoria, Johan Burisch, Gilaad G Kaplan, Xavier Calvet
BACKGROUND: Inflammatory bowel disease (IBD) has a major economic impact on healthcare costs. OBJECTIVES: The aim of this study was to evaluate the current healthcare expenditure associated with IBD in a population-wide study in Catalonia. DESIGN: Retrospective observational study. METHODS: All patients with IBD included in the Catalan Health Surveillance System (CHSS) were considered eligible. The CHSS compiles data on more than 7 million individuals in 2020 (34,823 with IBD)...
2024: Therapeutic Advances in Gastroenterology
#24
JOURNAL ARTICLE
Jihye Park, I Seul Park, Ji Hyung Kim, Jung Hyun Ji, Soo Jung Park, Jae Jun Park, Tae Il Kim, Seung Won Kim, Jae Hee Cheon
BACKGROUND: Notably, 5-aminosalicylates (5-ASA) are vital in treating inflammatory bowel diseases (IBD). The adverse events of 5-ASA rarely occur but they could be fatal. OBJECTIVES: We aimed to discover new genetic biomarkers predicting 5-ASA-induced adverse events in patients with IBD. DESIGN: This was a retrospective observational study. METHODS: We performed a genome-wide association study on patients with IBD in South Korea...
2024: Therapeutic Advances in Gastroenterology
#25
JOURNAL ARTICLE
Uria Shani, Niv Ben-Shabat, Roula Qassem, Adi Lahat, Mahmud Omar, Einat Savin, Arad Dotan, Yonatan Shneor Patt, Lior Fisher, Galia Zacay, Howard Amital, Abdulla Watad, Kassem Sharif
BACKGROUND: The skin-gut axis, characterized by bidirectional communication between the skin and gut, plays a crucial role in the pathogenesis of psoriasis and inflammatory bowel diseases (IBD). OBJECTIVES: We aimed to explore the association between psoriasis and IBD and identify predictors associated with IBD development among patients with psoriasis. DESIGN: Retrospective cohort study. METHODS: A retrospective study which utilized an electronic database from the Meuhedet Health Maintenance Organization (MHMO) in Israel...
2024: Therapeutic Advances in Gastroenterology
#26
JOURNAL ARTICLE
Wei Han, Jing Hu, Juan Wu, Peipei Zhang, Qiuyuan Liu, Naizhong Hu, Qiao Mei
BACKGROUND: It is unclear how clinical and endoscopic factors affect the attainment of endoscopic remission (ER) in patients with small bowel Crohn's disease (SB-CD) who are infliximab-naïve. OBJECTIVES: We aimed to identify the effect of different factors on attaining ER using double-balloon endoscopy (DBE) evaluation. DESIGN: A single-center retrospective observational study was conducted from 1 January 2018 to 30 November 2022. Among 262 patients who were screened for isolated SB-CD by baseline DBE, 108 patients were assessed for effectiveness during maintenance infliximab therapy by a second DBE evaluation...
2024: Therapeutic Advances in Gastroenterology
#27
JOURNAL ARTICLE
Mengqi Li, Sha Chen, Shuxiang Li, Tingting Lv, Buer Li, Shan Shan, Min Li, Na Zeng, Qianyi Wang, Yuanyuan Kong, Hong Ma, Xinyan Zhao, Xiaojuan Ou, Hong You, Weijia Duan, Jidong Jia
BACKGROUND: Mildly elevated levels of transaminase and/or immunoglobulin G (IgG) are common in patients with primary biliary cholangitis (PBC). It is still unclear whether adding immunosuppressive therapy to ursodeoxycholic acid (UDCA) benefits those patients who are not fulfilling the diagnostic criteria of PBC with autoimmune hepatitis (AIH) features. OBJECTIVES: To assess the efficacy of adding immunosuppressive therapy to UDCA for patients with PBC and autoimmune phenomena but not fulfilling the diagnostic criteria of PBC with AIH features...
2024: Therapeutic Advances in Gastroenterology
#28
JOURNAL ARTICLE
Dominique Béchade, Lola-Jade Palmieri, Benjamin Bonhomme, Simon Pernot, Jeanne Léna, Marianne Fonck, Sophie Pesqué, Gautier Boillet, Antoine Italiano, Gilles Roseau
BACKGROUND: The impact of KRAS mutation testing on pancreatic ductal adenocarcinoma (PDAC) samples by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for reducing the need to repeat EUS-FNA has been demonstrated. Such testing however is not part of standard practice for endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB). OBJECTIVES: We aim to analyse the proportion of non-contributive samples by EUS-FNB and to evaluate the impact of KRAS mutation testing on the diagnosis, theranostics and survival...
2024: Therapeutic Advances in Gastroenterology
#29
JOURNAL ARTICLE
Ran Jin, Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, Greg Kricorian, James L O'Kelly, Walter Reinisch
BACKGROUND: Approval of the adalimumab (ADA) biosimilar ABP 501 for inflammatory bowel disease (IBD) indications was based on the principle of extrapolation, without indication-specific clinical trial data. OBJECTIVES: To evaluate the real-world treatment patterns of ABP 501 in patients with IBD. DESIGN: Retrospective analysis of pharmacy claims data from Germany and France. METHODS: Continuously insured adult IBD patients who initiated ABP 501 between October 2018 and March 2020 were included...
2024: Therapeutic Advances in Gastroenterology
#30
JOURNAL ARTICLE
Shaoze Ma, Zhenhua Tong, Yong He, Yiyan Zhang, Xiaozhong Guo, Xingshun Qi
BACKGROUND: Barrett's esophagus (BE) is a precursor of esophageal adenocarcinoma. It is critical to recognize the risk factors associated with BE. OBJECTIVES: The present meta-analysis aims to systematically estimate the association of hiatal hernia with the risk of BE. DESIGN: A meta-analysis with trial sequential analysis. DATA SOURCES AND METHODS: The PubMed, EMBASE, and Cochrane Library databases were searched. The pooled odds ratios (ORs) and adjusted ORs (aORs) with their 95% confidence intervals (CIs) were calculated for the combined estimation of unadjusted data and data adjusted for confounders, respectively...
2024: Therapeutic Advances in Gastroenterology
#31
JOURNAL ARTICLE
Margalida Calafat, Paola Torres, Joan Tosca-Cuquerella, Rubén Sánchez-Aldehuelo, Montserrat Rivero, Marisa Iborra, María González-Vivo, Isabel Vera, Luisa de Castro, Luis Bujanda, Manuel Barreiro-de Acosta, Carlos González-Muñoza, Xavier Calvet, José Manuel Benítez, Mónica Llorente-Barrio, Gerard Surís, Fiorella Cañete, Lara Arias-García, David Monfort, Andrés Castaño-García, Francisco Javier Garcia-Alonso, José M Huguet, Ignacio Marín-Jímenez, Rufo Lorente, Albert Martín-Cardona, Juan Ángel Ferrer, Patricia Camo, Javier P Gisbert, Ramón Pajares, Fernando Gomollón, Jesús Castro-Poceiro, Jair Morales-Alvarado, Jordina Llaó, Andrés Rodríguez, Cristina Rodríguez, Pablo Pérez-Galindo, Mercè Navarro, Nuria Jiménez-García, Marta Carrillo-Palau, Isabel Blázquez-Gómez, Eva Sesé, Pedro Almela, Patricia Ramírez de la Piscina, Carlos Taxonera, Iago Rodríguez-Lago, Lidia Cabrinety, Milagros Vela, Miguel Mínguez, Francisco Mesonero, María José García, Mariam Aguas, Lucía Márquez, Marisol Silva Porto, Juan R Pineda, Koldo García-Etxebarría, Federico Bertoletti, Eduard Brunet, Míriam Mañosa, Eugeni Domènech
BACKGROUND: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF. OBJECTIVES: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. DESIGN: Retrospective observational study. METHODS: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially)...
2024: Therapeutic Advances in Gastroenterology
#32
REVIEW
Yohei Funayama, Satoshi Shinozaki, Tomonori Yano, Hironori Yamamoto
Before the development of double-balloon enteroscopy (DBE), the standard management of small-bowel polyposis was surgical resection. This is an invasive procedure that could lead to short bowel syndrome. In the 21st century, several new enteroscopy techniques were distributed worldwide, including DBE, single-balloon enteroscopy, spiral enteroscopy, and motorized spiral enteroscopy. These devices enable the diagnoses and endoscopic interventions in the entire small bowel, even in patients with a history of laparotomy...
2024: Therapeutic Advances in Gastroenterology
#33
JOURNAL ARTICLE
Francesco Vitali, Timo Rath, Entcho Klenske, Anna-Lena Vögele, Ingo Ganzleben, Sebastian Zundler, Deike Strobel, Carol Geppert, Arndt Hartmann, Markus F Neurath, Raja Atreya
BACKGROUND: Effective management of patients with acute severe ulcerative colitis (ASUC) is a major challenge and there remains a paucity of available maintenance treatment options after efficacious cyclosporin induction therapy. OBJECTIVES: We investigated the long-term effectiveness and safety of cyclosporin and ustekinumab combination therapy in patients with steroid refractory ASUC. DESIGN: Monocentric, prospective study. METHODS: We included patients with steroid refractory ASUC with multiple failed prior advanced therapies, who were treated with cyclosporin and ustekinumab combination therapy...
2024: Therapeutic Advances in Gastroenterology
#34
JOURNAL ARTICLE
Nanja Bevers, Arta Aliu, Dennis R Wong, Bjorn Winkens, Anita Vreugdenhil, Marieke J Pierik, Luc J J Derijks, Patrick F van Rheenen
BACKGROUND: Exposure-response studies have shown that higher infliximab concentrations are associated with better outcomes in inflammatory bowel disease. There is little agreement about the optimal time to measure infliximab levels in children. OBJECTIVES: We aimed to evaluate whether trough levels at week 6 or week 14 predict sustained remission. The secondary aim was to define target trough levels at weeks 6 and 14. DESIGN: We used routinely collected electronic healthcare data of 70 anti-tumour necrosis factor naïve children with inflammatory bowel disease treated with a standard infliximab induction- and variable maintenance scheme...
2024: Therapeutic Advances in Gastroenterology
#35
REVIEW
Eyal Klang, Ali Sourosh, Girish N Nadkarni, Kassem Sharif, Adi Lahat
BACKGROUND: The integration of artificial intelligence (AI) into healthcare has opened new avenues for enhancing patient care and clinical research. In gastroenterology, the potential of AI tools, specifically large language models like ChatGPT, is being explored to understand their utility and effectiveness. OBJECTIVES: The primary goal of this systematic review is to assess the various applications, ascertain the benefits, and identify the limitations of utilizing ChatGPT within the realm of gastroenterology...
2023: Therapeutic Advances in Gastroenterology
#36
JOURNAL ARTICLE
Application of deep learning in the diagnosis and evaluation of ulcerative colitis disease severity.
Xinyi Jiang, Xudong Luo, Qiong Nan, Yan Ye, Yinglei Miao, Jiarong Miao
BACKGROUND: Achieving endoscopic and histological remission is a critical treatment objective in ulcerative colitis (UC). Nevertheless, interobserver variability can significantly impact overall assessment performance. OBJECTIVES: We aimed to develop a deep learning algorithm for the real-time and objective evaluation of endoscopic disease activity and prediction of histological remission in UC. DESIGN: This is a retrospective diagnostic study...
2023: Therapeutic Advances in Gastroenterology
#37
JOURNAL ARTICLE
Flavio Steinwurz, Marta Brenner Machado, Guillermo Veitia, Juan Andres De Paula, Socrates Bautista Martinez, Beatriz Iade Vergara, Beatriz Capdevielle, Francisca Ana Martinez Silva, Ana Luz Ramirez
BACKGROUND: Inflammatory bowel diseases (IBDs) are chronic conditions that negatively interferes with the quality of life of the patients, on a physical, emotional, and social level. Its symptoms can vary including diarrhea, bleeding, abdominal pain, fever, and weight loss, depending on the type and location and severity of the disease. Despite evolving treatment, they do not always achieve control of the symptoms, so between 23% and 45% of people with idiopathic chronic ulcerative colitis, and up to 75% of those with Crohn's disease, eventually, will need surgery...
2023: Therapeutic Advances in Gastroenterology
#38
REVIEW
Aditi Kumar, Nuha Yassin, Alexandra Marley, Vittoria Bellato, Caterina Foppa, Gianluca Pellino, Pär Myrelid, Monica Millan, Beatriz Gros, Nicolas Avellaneda, Ignacio Catalan-Serra, Alaa El-Hussuna, João A Cunha Neves, Joana Roseira, Miguel F Cunha, Bram Verstockt, Dominik Bettenworth, Diane Mege, Matthew J Brookes
An estimated 2.5-3 million individuals (0.4%) in Europe are affected by inflammatory bowel disease (IBD). Whilst incidence rates for IBD are stabilising across Europe, the prevalence is rising and subsequently resulting in a significant cost to the healthcare system of an estimated 4.6-5.6 billion euros per year. Hospitalisation and surgical resection rates are generally on a downward trend, which is contrary to the rising cost of novel medication. This signifies a large part of healthcare cost and burden...
2023: Therapeutic Advances in Gastroenterology
#39
JOURNAL ARTICLE
Pengwei Liu, Jie Wu, Chiyi He, Wei Wang
BACKGROUND: Recently, the ENDOANGEL (EN) system, a computer-assisted detection technique, and water exchange (WE) assisted colonoscopy have both been shown to increase the colorectal adenoma detection rate (ADR). OBJECTIVES: The aim of this study was to compare the ADR between EN- and WE-assisted colonoscopy. DESIGN: This was a retrospective study. METHODS: Data from patients who underwent either EN- or WE-assisted colonoscopy between October 2021 and August 2022 were analysed consecutively...
2023: Therapeutic Advances in Gastroenterology
#40
JOURNAL ARTICLE
Jian Wan, Jun Shen, Xiaoping Wu, Jie Zhong, Yan Chen, Lanxiang Zhu, Yinglei Miao, Naizhong Hu, Jie Chen, Jie Liang, Kaichun Wu
BACKGROUND: The incidence of inflammatory bowel disease (IBD) is rapidly increasing in China, a vast country with significant geographical differences. The socioeconomic status of Eastern China is significantly higher than that of Western China. OBJECTIVES: This study aimed to describe the geographical heterogeneity in the characteristics and management of patients with IBD in both Eastern and Western China. DESIGN: This was a multicenter, cross-sectional study...
2023: Therapeutic Advances in Gastroenterology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
